Vanguard Group
BRTX icon

Vanguard Group’s BioRestorative Therapies BRTX Stock Holding History

Vanguard Group’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$104K Hold
88,778
– – ﹤0.01% 4173
2025
Q3 		$127K Buy
88,778
+59,048
+199% +$91.4K ﹤0.01% 4194
2025
Q2 		$49.6K Hold
29,730
– – ﹤0.01% 4198
2025
Q1 		$52.9K Buy
29,730
+9,258
+45% +$17.7K ﹤0.01% 4188
2024
Q4 		$29.3K Hold
20,472
– – ﹤0.01% 4239
2024
Q3 		$35.6K Hold
20,472
– – ﹤0.01% 4267
2024
Q2 		$41.6K Hold
20,472
– – ﹤0.01% 4305
2024
Q1 		$28.3K Sell
20,472
-100,161
-83% -$154K ﹤0.01% 4363
2023
Q4 		$210K Sell
120,633
-17,185
-12% -$32.8K ﹤0.01% 4217
2023
Q3 		$247K Buy
137,818
+10,862
+9% +$27.4K ﹤0.01% 4213
2023
Q2 		$560K Buy
126,956
+1,000
+0.8% +$4.79K ﹤0.01% 4087
2023
Q1 		$428K Sell
125,956
-9,090
-7% -$27.9K ﹤0.01% 4166
2022
Q4 		$371K Hold
135,046
– – ﹤0.01% 4178
2022
Q3 		$436K Hold
135,046
– – ﹤0.01% 4251
2022
Q2 		$398K Hold
135,046
– – ﹤0.01% 4341
2022
Q1 		$706K Sell
135,046
-17,408
-11% -$75.1K ﹤0.01% 4305
2021
Q4 		$662K Buy
+152,454
New +$871K ﹤0.01% 4370

Other funds holding BRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Vanguard Group's BRTX Position: Q4 2025 in Review

Vanguard Group held its BioRestorative Therapies (BRTX) position steady in Q4 2025 at 88,778 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4173.

Vanguard Group first reported a position in BRTX in Q4 2021 and has held it in 17 quarters since. The position peaked at $706K in Q1 2022. 13 funds tracked by Wall St. Rank hold BRTX as of Q4 2025.

  • Vanguard Group held 88,778 shares of BioRestorative Therapies worth $104K as of Q4 2025.
  • Vanguard Group left its BioRestorative Therapies share count unchanged in Q4 2025.
  • BioRestorative Therapies made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4173 holding.
  • Vanguard Group first reported a position in BioRestorative Therapies in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's BioRestorative Therapies position peaked at $706K in Q1 2022.
  • 13 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.